Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 19/20 | 0.89 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.77 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.77 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476080 | 1.00 | BCL2 (0.89) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1956445 | 0.95 | BCL2 (0.91) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1956446 | 0.95 | BCL2 (0.91) | BCL2BCL2L1MCL1TMEM97BCL2L2 | |
| SCHEMBL1956998 | 0.95 | BCL2 (0.92) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL1956944 | 0.95 | BCL2 (0.88) | BCL2 | |
| SCHEMBL1956939 | 0.95 | BCL2 (0.88) | BCL2 | |
| SCHEMBL1956936 | 0.95 | BCL2 (0.88) | BCL2 | |
| SCHEMBL1955865 | 0.95 | BCL2 (0.87) | BCL2 | |
| SCHEMBL1959292 | 0.94 | BCL2 (1.00) | BCL2 | |
| SCHEMBL1959289 | 0.94 | BCL2 (1.00) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2020-07-16 | — | — | US | claimed |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2018-12-27 | — | — | US | claimed |
| US-9872861-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2018-01-23 | — | — | US | claimed |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2017-08-17 | — | — | US | claimed |
| EP-3112361-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| US-20160235760-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | claimed |
| EP-3028702-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | AbbVie Bahamas Limited (BS) | 2016-06-08 | — | — | EP | claimed |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | claimed |
| US-8952157-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20140088106-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2014-03-27 | — | — | US | claimed |
| US-20140066621-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2014-03-06 | — | — | US | claimed |
| EP-2642999-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | AbbVie Inc. (US) | 2013-10-02 | — | — | EP | claimed |
| WO-2012071374-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-31 | — | — | WO | claimed |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | US | claimed |
| EP-2376197-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-10-19 | — | — | EP | claimed |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | claimed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | claimed |
| US-20250302827-A1 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | UNIV EMORY (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2010065824-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885BCL2L1 2/4885MCL1 21/4885 |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885BCL2L1 2/4885MCL1 21/4885 |
| US-20160235760-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885BCL2L1 2/4885MCL1 21/4885 |
| US-20140088106-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20250302827-A1 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885BCL2L1 3/4885MCL1 8/4885 |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885BCL2L1 2/4885MCL1 21/4885 |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885BCL2L1 2/4885MCL1 23/4885 |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885BCL2L1 2/4885MCL1 21/4885 |
| US-20140066621-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | BCL2 1/4885BCL2L1 4/4885MCL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.